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Confirmation of the utility of the International
Staging System and identification of a unique
pattern of disease in Brazilian patients with
multiple myeloma
Multiple myeloma (MM) is one of the most fre-
quent hematologic malignancies, and its incidence
varies worldwide. Except for occasional case series or
correlative biological studies, little is known about the
incidence and clinical features of MM in Latin
America. In Brazil, national estimates for the inci-
dence of MM are currently unavailable. Sixteen
Brazilian institutions provided information on
patients diagnosed with MM between 1998 and
2004. The investigators included all patients whose
charts were available. All patients were undergoing
care at these institutions. The diagnosis was based on
the new criteria,1 and/or standard clinical, laboratory
and radiographical features, as well as on bone mar-
row findings compatible with MM. Since the majori-
ty of patients had Durie-Salmon stage (DSS) III, the
diagnosis was not in doubt. Patients’ data were
obtained from institutional charts, and were entered
on a web-based system specifically designed for the
study under the auspices of the International
Myeloma Foundation. We collected information
regarding the demographical features of the patient,
date of diagnosis, stage according to the DSS2 and
ISS,3 type of monoclonal component, results of perti-
nent laboratory tests, type of treatment administered,
and date of last follow-up or death. From 1998 to
2004, the patients who were not candidates for high-
dose chemotherapy (i.e., those who presented with
poor performance status or for whom high-dose
chemotherapy was not available) were treated with
melphalan and prednisone. 
The database was analyzed in August 2006. A total
number of 1,112 patients were included. χ2 tests were
used for the comparisons between proportions.
Survival, defined from the date of diagnosis until
death, was analyzed by the Kaplan-Meier method4
and survival curves were compared using the log-rank
test.5 Patients who were alive on the last visit or who
were lost to follow-up were censored for survival
analyses. Significant baseline univariate predictors of
survival in the Kaplan-Meier analyses were consid-
ered for inclusion in a Cox regression model.6
Backward selection of all factors was used, and a vari-
able was retained in the model if the associated two-
sided p value was ≤0.05. All statistical tests were two-
sided, and final p values ≤0.05 were considered signif-
icant.
Main demographical and clinical features of the
patients are shown in Table 1. The median follow-up
was 20.5 months, and the estimated median overall
survival was 57.7 months. At the time of the analysis,
392 patients (35.3%) were already deceased. Overall
survival was analyzed according to DSS and ISS
(Figure 1, Panels A and B). There was a statistically
significant difference between the overall survival of
patients with MM in stages I, II and III according to
both staging systems (p<0.001). With DSS, however,
there was a considerable overlap between the sur-
vival curves for patients in stage I and II (Figure 1,
Panel A). The median overall survival for patients in
DSS I and II had not been reached at the time of the
analysis; for patients in stage III, the median overall
survival was 52.1 months. After 5 years, the estimat-
ed proportions of survival for patients in DSS stages I,
II and III were 73.3%, 54.7% and 44.3% respectively.
The survival curves for patients in ISS stages I, II
and III are clearly distinct, with no overlap until 100
months of follow-up (Figure 1, Panel B). In addition,
20.1%, 48.7% and 31.2% of patients were in ISS I, II
and III respectively. Corresponding proportions in the
ISS database were 28.9%, 37.5% and 33.6% respec-
tively.3 The median overall survival for patients in ISS
stage I had not been reached at the time of the analy-
sis; for patients in stages II and III, median overall sur-
vival was 65.5 and 26.0 months respectively.
Corresponding figures in the original ISS database
were 62, 44 and 29 months respectively. After 5
years, the estimated proportions of survival for
patients in ISS stages I, II and III were 68.2%, 52.7%
and 30.4% respectively.
The differences between the survival of our
patients in stages I and II and the corresponding
patients from the original ISS database may reflect
patient selection, treatment modalities, or be due to
chance. Our database contains a lower proportion of
patients in stage I, and a higher proportion in stage II,
but these differences are unlikely to have contributed
to the longer overall survival observed in the current
study. In the ISS database, 26.1% of patients received
high-dose chemotherapy within nine months of diag-
nosis, figures very similar to those found in the pres-
ent study (25.5%). We, therefore,  cannot explain the
survival difference observed for patients in this study
and patients included in the ISS database.
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Table 1. Patients’ characteristics (n=1112).
Characteristic Information available (N) N (%)
Age, median (range) 1112 60.5 years (28 – 94)
Sex 1112
Female 553 (49.7)
Male 559 (50.3)
Ethnicity 1112
Caucasian/mixed 926 (83.3)
African 176 (15.8)
Other 10 (0.9)
Creatinine 1004
> 2 mg/dL 231 (23)
≤ 2 mg/dL 773 (77)
Immunoglobulin (Ig) isotype 926
IgG 570 (61.5)
IgA 181 (19.5)
IgM 3 (0.3)
Light-chain only 112 (12.1)
Non-secretory 40 (4.3)
Hemoglobin 1007
<10 g/dL 585 (58)
Bone lesions 1043
Absent 155 (14.9)
Present 888 (85.1)
Durie-Salmon stage 1066
I 68 (6.4)
II 182 (17.1)
III 816 (76.5)
International Staging System stage 756
I 152 (20.1)
II 368 (48.7)
III 236 (31.2)
Hypercalcemia 1003
Absent 764 (76.2)
Present 239 (23.8)
High-dose chemotherapy 1057
Yes 270 (25.5)
No 787 (74.5)
Letters to the Editor
| 792 | haematologica | 2008; 93(5)
Interestingly, no patients from Brazil or any other
Latin American countries were included in the origi-
nal ISS database.
When survival was analyzed according to other
potential prognostic factors, age >60 years (52.1 vs.
65.5 months for those with age ≤60 years), presence
of hypercalcemia (21.3 vs. 63.9 months for those with
normal serum calcium) and receipt of high-dose
chemotherapy (82.2 vs. 43.5 months for patients not
treated with high-dose chemotherapy) were found to
be significantly associated with increased mortality
(p<0.001 in all cases). Age and receipt of high-dose
chemotherapy were correlated: 83.0% of patients
undergoing high-dose chemotherapy were aged ≤60
years, whereas 62.9% of patients not treated with
high-dose chemotherapy were aged > 60 years
(p<0.001).
The multivariate prognostic model included
patients’ baseline variables that were associated with
mortality in the Kaplan-Meier univariate analyses.
Only hypercalcemia, ISS stage III and age were inde-
pendent predictors of mortality (Table 2). According
to the model, DSS had no independent prognostic
role when hypercalcemia, ISS and age were consid-
ered simultaneously. 
The current study, which is the largest case series of
MM in Brazil, identifies the unique aspect of the pat-
tern of disease for Brazilian myeloma patients, with
hypercalcemia as the main risk. It recognizes the fea-
sibility of large, collaborative, observational studies
between various tertiary-care hematology centers,
and confirms that ISS is indeed a more useful prog-
nostic index than the DSS system in Brazilian
patients.
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Table 2. Multivariate prognostic model for mortality.
Variable Category Hazard ratio 95% confidence p 
interval value
Hypercalcemia Absent 1.00
Present 2.47 1.86–3.28 <0.001
ISS stage I 1.00
II 1.22 0.79–1.88 0.364
III 2.40 1.55–3.72 <0.001
Age ≤ 60 years 1.00
> 60 years 1.54 1.18–2.01 0.002
Durie-Salmon stage I 1.00
II 0.97 0.44–2.12 0.939
III 1.28 0.63–2.60 0.501
ISS: International Staging System. 
Figure 1. Overall survival according to the Durie-Salmon Staging
(DSS) system (Panel A, N=1,066) and to the International Staging
system (ISS; Panel B, N=756).
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